PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW

Documenti analoghi

• Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
  di: Hossein Karami, et al.
  Pubblicazione: (2017-01-01)
• PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW
  di: A. Kattamis, et al.
  Pubblicazione: (2022-06-01)
• Deferiprone or deferasirox for cardiac siderosis in β thalassemia major (reply)
  di: Alessia Pepe, et al.
  Pubblicazione: (2011-02-01)
• Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major
  di: Khaled M. Musallam, et al.
  Pubblicazione: (2011-02-01)
• Dual oral iron chelation with deferasirox and deferiprone in transfusion-dependent β-thalassemia: a narrative review of efficacy, safety, and practical application
  di: Vinson James, et al.
  Pubblicazione: (2026-04-01)